Q-omics provides the consensus-scored MTCYBP19 profile across patient tissues and cancer cell-line models. MTCYBP19 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in CHOL. Among the 18 cancer types available for tumor–normal comparison, MTCYBP19 is differentially expressed in 2, with the highest sampling consensus in STAD. Additionally, MTCYBP19 RNA expression shows 4,745 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight CHOL, and STAD as cancer lineages where MTCYBP19 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MTCYBP19 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MTCYBP19 survival associations across molecular data types. MTCYBP19 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MTCYBP19 RNA expression–survival associations across cancer types. High MTCYBP19 expression shows unfavorable associations in CHOL, STAD, ACC, TGCT and COAD, but favorable associations in CESC. The CHOL Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify CHOL as the clearest survival context for MTCYBP19 RNA expression.
This table summarizes MTCYBP19 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for MTCYBP19. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MTCYBP19 shows lower tumor expression in STAD and LIHC. The STAD box plot shows higher MTCYBP19 RNA expression in normal versus tumor tissue (log2 FC = −0.065, t-test p = .049).
This table shows molecular features associated with MTCYBP19 in patient tissues and cancer cell lines. In patient samples, MTCYBP19 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
